Chemical structure-guided design of dynapyrazoles, potent cell-permeable dynein inhibitors with a unique mode of action
- Rockefeller University, United States
- Feinberg School of Medicine, Northwestern University, United States
- Tri-Institutitional Therapeutics Discovery Institute, United States
- Takeda Pharmaceuticals Ltd., Japan
- MRC Laboratory of Molecular Biology, United Kingdom
- California Institute of Technology, United States
- Stanford University, United States
- Stanford University School of Medicine, United States
- Northwestern University, United States
Abstract
Cytoplasmic dyneins are motor proteins in the AAA+ superfamily that power transport of cellular cargos towards microtubule minus-ends. Recently, ciliobrevins were reported as selective cell-permeable inhibitors of cytoplasmic dyneins. As is often true for first-in-class inhibitors, the use of ciliobrevins has been limited by low potency. Moreover, suboptimal chemical properties, such as the potential to isomerize, have hindered efforts to improve ciliobrevins. Here, we characterized the structure of ciliobrevins and designed conformationally-constrained isosteres. We identified dynapyrazoles, inhibitors more potent than ciliobrevins in vitro, and find that while ciliobrevins inhibit both dynein's microtubule-stimulated and basal ATPase activity, dynapyrazoles block only microtubule-stimulated activity. Single-digit micromolar concentrations of dynapyrazoles block intraflagellar transport in the cilium and lysosome motility in the cytoplasm, processes that depend on cytoplasmic dyneins. Together, our studies suggest that chemical structure-based analyses can lead to inhibitors with distinct modes of inhibition and improved properties.
Article and author information
Author details
Funding
National Institutes of Health (R01 GM098579)
- Tarun M Kapoor
Robertson Therapeutic Development Fund
- Tarun M Kapoor
Damon Runyon Cancer Research Foundation (DRG-2222-15)
- Rand M Miller
Medical Research Council (MC_UP_A025_1011)
- Andrew P Carter
National Institutes of Health (T32GM007739)
- Jonathan Baruch Steinman
National Institutes of Health (R01 GM52111)
- Vladimir I Gelfand
National Institutes of Health (R01 GM113100)
- James K Chen
Wellcome (WT100387)
- Andrew P Carter
National Institutes of Health (R01 GM089933)
- Maxence V Nachury
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Wilfred A van der Donk, University of Illinois at Urbana-Champaign, United States
Publication history
- Received: January 20, 2017
- Accepted: May 17, 2017
- Accepted Manuscript published: May 19, 2017 (version 1)
- Version of Record published: June 20, 2017 (version 2)
Copyright
© 2017, Steinman et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 4,008
- Page views
-
- 674
- Downloads
-
- 15
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Chemical structure-guided design of dynapyrazoles, potent cell-permeable dynein inhibitors with a unique mode of action
eLife 6:e25174.
https://doi.org/10.7554/eLife.25174
Further reading
-
- Biochemistry and Chemical Biology
Ciliopathies manifest from sensory abnormalities to syndromic disorders with multi-organ pathologies, with retinal degeneration a highly penetrant phenotype. Photoreceptor cell death is a major cause of incurable blindness in retinal ciliopathies. To identify drug candidates to maintain photoreceptor survival, we performed an unbiased, high-throughput screening of over 6,000 bioactive small molecules using retinal organoids differentiated from induced pluripotent stem cells (iPSC) of rd16 mouse, which is a model of Leber congenital amaurosis (LCA) type 10 caused by mutations in the cilia-centrosomal gene CEP290. We identified five non-toxic positive hits, including the lead molecule reserpine, which maintained photoreceptor development and survival in rd16 organoids. Reserpine also improved photoreceptors in retinal organoids derived from induced pluripotent stem cells of LCA10 patients and in rd16 mouse retina in vivo. Reserpine-treated patient organoids revealed modulation of signaling pathways related to cell survival/death, metabolism, and proteostasis. Further investigation uncovered dysregulation of autophagy associated with compromised primary cilium biogenesis in patient organoids and rd16 mouse retina. Reserpine partially restored the balance between autophagy and the ubiquitin-proteasome system at least in part by increasing the cargo adaptor p62, resulting in improved primary cilium assembly. Our study identifies effective drug candidates in preclinical studies of CEP290 retinal ciliopathies through cross-species drug discovery using iPSC-derived organoids, highlights the impact of proteostasis in the pathogenesis of ciliopathies, and provides new insights for treatments of retinal neurodegeneration.
-
- Biochemistry and Chemical Biology
Mutations within Ras proteins represent major drivers in human cancer. In this study, we report the structure-based design, synthesis, as well as biochemical and cellular evaluation of nucleotide-based covalent inhibitors for KRasG13C, an important oncogenic mutant of Ras that has not been successfully addressed in the past. Mass spectrometry experiments and kinetic studies reveal promising molecular properties of these covalent inhibitors, and X-ray crystallographic analysis has yielded the first reported crystal structures of KRasG13C covalently locked with these GDP analogues. Importantly, KRasG13C covalently modified with these inhibitors can no longer undergo SOS-catalysed nucleotide exchange. As a final proof-of-concept, we show that in contrast to KRasG13C, the covalently locked protein is unable to induce oncogenic signalling in cells, further highlighting the possibility of using nucleotide-based inhibitors with covalent warheads in KRasG13C-driven cancer.
